Biosimilars Market
完整報告名稱與涵蓋範圍
Biosimilars Market by Drug Class (mAbs [Adalimumab, Infliximab, Rituximab, Trastuzumab], GCSF, Insulin, Anticoagulant, rhGH, Teriparatide, GLP-1), Indication (Oncology, Autoimmune, Diabetes, Obesity), Competitive Landscape, Region - Global Forecast to 2036
報告摘要
The biosimilars market is projected to reach USD 70.79 billion by 2036 from an estimated USD 37.39 billion in 2026, registering a CAGR of 6.6% during the forecast period. Market growth is primarily driven by increasing awareness and education regarding the safety, efficacy, and interchangeability of biosimilars, resulting in increased acceptance among healthcare providers and patients. In parallel, favorable insurance coverage and reimbursement policies across public and private healthcare systems are supporting broader adoption by improving the affordability and accessibility of biosimilar therapies. The growing need to reduce healthcare expenditure and expand patient access to cost-effective biologic treatments is further accelerating demand.
However, the market's expansion is constrained by the increasing complexity of biosimilar development and manufacturing, which requires sophisticated technologies, stringent quality controls, and substantial investment. In addition, the growing number of biosimilars competing within the same therapeutic categories is intensifying price competition and margin pressure, particularly in mature markets. These factors are expected to moderate market growth over the forecast period despite continued expansion in biosimilar utilization and market penetration.
The monoclonal antibodies segment is expected to witness the highest growth rate during the study period.
By drug class, the monoclonal antibodies (mAbs) segment is expected to register the highest CAGR during the forecast period, supported by the extensive use of biologics such as Infliximab, Rituximab, Adalimumab, Trastuzumab, Pembrolizumab, Dupilumab, Ustekinumab, Risankizumab, Daratumumab, Nivolumab, and other mAbs across oncology, autoimmune diseases, chronic inflammatory conditions, and selected infectious diseases. The growing prevalence of cancer and autoimmune disorders, combined with an expanding eligible patient population and increasing utilization of biologic therapies, is expected to strengthen demand for mAb biosimilars. In addition, the anticipated loss of patent and regulatory exclusivity for several high-value reference biologics will create opportunities for biosimilar manufacturers to enter large and established therapeutic markets.
mAbs are widely used in the management of cancer, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other chronic and potentially life-threatening conditions, with demand further supported by an aging population and the increasing burden of chronic diseases. The availability of biosimilar alternatives can reduce treatment costs, expand patient access, and encourage greater utilization of biologic therapies, particularly in cost-sensitive healthcare systems. Over the next decade, the expected loss of exclusivity of multiple high-value mAbs is likely to attract additional pharmaceutical and biotechnology companies, intensifying competition and expanding the global biosimilar landscape. The broad therapeutic applicability and substantial commercial value of mAb reference products, particularly across oncology and immunology, are therefore expected to make monoclonal antibody biosimilars a major contributor to market growth through 2036.
The US is expected to register the highest CAGR during the forecast period.
By country, the US is expected to register the highest CAGR in the global biosimilars market between 2026 and 2036, supported by the growing number of biosimilar launches, loss of exclusivity of high-value biologics, increasing payer acceptance, and continued development of the regulatory framework under the Biologics Price Competition and Innovation Act (BPCIA). The US market is entering a period of significant biosimilar expansion as additional reference biologics lose patent and regulatory exclusivity, creating opportunities across high-value therapeutic areas such as oncology, immunology, ophthalmology, and endocrinology.
The commercialization of biosimilars to major biologics, including Stelara (ustekinumab), Eylea (aflibercept), and other high-value reference products, is expected to substantially expand the addressable market during the forecast period. The US has already demonstrated strong competitive activity following the introduction of biosimilars to Humira (adalimumab) beginning in 2023, with multiple manufacturers, including Amgen, Boehringer Ingelheim, and Sandoz, entering the market. Increasing competition among manufacturers has contributed to lower prices and broader payer and formulary access, while interchangeability designations for selected biosimilars can further facilitate substitution and adoption.
In addition, growing awareness among physicians, patients, payers, and healthcare providers, together with federal initiatives aimed at improving affordability and reducing healthcare expenditure, is expected to support continued biosimilar uptake. As the number of interchangeable biosimilars increases and stakeholders gain greater experience with switching between reference biologics and biosimilars, adoption is expected to accelerate. These factors, combined with the large US biologics market, high healthcare expenditure, substantial eligible patient population, and continued influx of biosimilar competitors, are expected to position the US as one of the fastest-growing and most commercially attractive markets for biosimilars through 2036.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Key players in the biosimilars market include Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion Inc. (South Korea), Biocon Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), Stada Arzneimittel AG (Germany), Boehringer Ingelheim International GmbH (Germany), Samsung Bioepis Co., Ltd. (South Korea), Amneal Pharmaceuticals, Inc. (US), Bio-Thera Solutions, Ltd. (China), Aprogen Inc. (South Korea), Shanghai Henlius Biotech, Inc. (China), and Alvotech (Iceland).
Research Coverage:
This research report categorizes the biosimilars market by drug class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor (G-CSF), Insulin, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Anticoagulants, Aflibercept, GLP-1 Agonist, and Other Drug Classes), indication (Oncology, Inflammatory & Autoimmune Diseases, Chronic Diseases, Blood Disorders, Growth Hormone Deficiencies, Infectious Diseases, Type II Diabetes, Obesity, and Other Indications), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimilars market. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, products, solutions, key strategies, collaborations, partnerships, and agreements.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape, gain more insights into better positioning of their businesses, and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
• Analysis of key drivers (Patent expiry of blockbuster biologics, Healthcare cost-containment & favorable reimbursement policies, Increasing physician & patient acceptance of biosimilars, Regulatory harmonization & faster biosimilar approval pathways), restraints (Price erosion due to intense biosimilar competition, High development & manufacturing costs, Regulatory complexity across emerging markets, Limited physician confidence in certain regions), opportunities (Next-wave patent expiries of high-value biologics, Expansion into emerging markets, Interchangeability & automatic pharmacy substitution, Government incentives for domestic biologics manufacturing), and challenges (Intensifying competition among biosimilar manufacturers, Originator lifecycle management strategies, Manufacturing capacity & supply chain complexity).
• Product Development/Innovation: Detailed insights into upcoming technologies and research & development activities in the biosimilars market.
• Market Development: Comprehensive information about lucrative markets. The report analyses the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biosimilars market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been carried out to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investments & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the biosimilars market.
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
目錄 Table of Contents
1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 38
1.3 INCLUSIONS AND EXCLUSIONS 38
1.4 STUDY SCOPE 39
1.4.1 SEGMENTS CONSIDERED 39
1.4.2 YEARS CONSIDERED 40
1.4.3 CURRENCY CONSIDERED 40
1.5 STAKEHOLDERS 40
1.6 SUMMARY OF CHANGES 41
2 EXECUTIVE SUMMARY 42
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 42
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS IN BIOSIMILARS MARKET 45
2.4 HIGH-GROWTH SEGMENTS 46
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 49
3.1 BIOSIMILARS MARKET OVERVIEW 49
3.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS 50
3.3 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
3.4 BIOSIMILARS MARKET SHARE, BY INDICATION, 2026 VS. 2036 (%) 51
4 MARKET OVERVIEW 52
4.1 INTRODUCTION 52
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 53
4.2.1.1 Patent Expiry of Blockbuster Biologics 53
4.2.1.2 Healthcare Cost-Containment and Favorable Reimbursement Policies 54
4.2.1.3 Increasing Physician and Patient Acceptance of Biosimilars 54
4.2.1.4 Regulatory Harmonization and Faster Biosimilar Approval Pathways 55
4.2.2 RESTRAINTS 55
4.2.2.1 Price Erosion Due to Intense Biosimilar Competition 55
4.2.2.2 High Development and Manufacturing Costs 56
4.2.2.3 Regulatory Complexity Across Emerging Markets 56
4.2.2.4 Limited Physician Confidence in Certain Regions 56
4.2.3 OPPORTUNITIES 57
4.2.3.1 Next-Wave Patent Expiries of High-Value Biologics 57
4.2.3.2 Expansion into Emerging Markets 57
4.2.3.3 Interchangeability & Automatic Pharmacy Substitution 58
4.2.3.4 Government Incentives for Domestic Biologics Manufacturing 58
4.2.4 CHALLENGES 59
4.2.4.1 Intensifying Competition Among Biosimilar Manufacturers 59
4.2.4.2 Originator Lifecycle Management Strategies 59
4.2.4.3 Manufacturing Capacity & Supply Chain Complexity 59
4.3 UNMET NEEDS & WHITE SPACES 60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 63
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 66
5.1.3 BARGAINING POWER OF BUYERS 66
5.1.4 BARGAINING POWER OF SUPPLIERS 66
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 67
5.2.1 INTRODUCTION 67
5.2.2 GDP TRENDS AND FORECAST 67
5.2.3 TRENDS IN GLOBAL BIOSIMILARS MARKET 67
5.2.4 TRENDS IN HEALTHCARE EXPENDITURE 68
5.3 VALUE CHAIN ANALYSIS 70
5.4 SUPPLY CHAIN ANALYSIS 71
5.5 ECOSYSTEM ANALYSIS 73
5.5.1 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS 75
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,
BY KEY PLAYER, 2023–2025 76
5.6.2 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,
BY REGION, 2023–2025 77
5.7 KEY CONFERENCES & EVENTS 79
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 80
5.9 INVESTMENT/FUNDING ACTIVITY 81
5.10 CASE STUDY ANALYSIS 82
5.11 IMPACT OF 2025 US TARIFF ON BIOSIMILARS MARKET 84
5.11.1 INTRODUCTION 84
5.11.2 KEY TARIFF RATES 84
5.11.3 PRICE IMPACT ANALYSIS 85
5.11.4 IMPACT ON COUNTRY/REGION 86
5.11.4.1 North America 86
5.11.4.1.1 US 86
5.11.4.2 Europe 86
5.11.4.3 Asia Pacific 87
5.11.5 IMPACT ON UPSTREAM MANUFACTURING INDUSTRIES 87
5.12 PIPELINE ANALYSIS 88
5.12.1 BIOSIMILAR PRODUCTS IN CLINICAL PIPELINE 88
5.13 LIST OF KEY BIOLOGICS TO GO OFF-PATENT 89
5.14 LIST OF BIOSIMILARS MANUFACTURING FACILITIES, BY KEY PLAYER 91
5.15 MANUFACTURING FACILITY EXPANSION 93
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 96
6.1 TECHNOLOGY ANALYSIS 96
6.1.1 KEY TECHNOLOGIES 96
6.1.1.1 Advanced bioprocessing & manufacturing technologies 96
6.1.1.2 Analytical & characterization techniques 96
6.1.2 COMPLEMENTARY TECHNOLOGIES 97
6.1.2.1 AI & ML 97
6.1.2.2 Lab automation & robotics 97
6.1.3 ADJACENT TECHNOLOGIES 97
6.1.3.1 Microbial fermentation 97
6.1.3.2 3D bioprinting & high-density cell culture 98
6.2 FUTURE APPLICATIONS 99
6.3 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET 100
6.3.1 TOP USE CASES AND MARKET POTENTIAL 100
6.3.1.1 Accelerated Drug Development and Reduced Costs 100
6.3.1.2 Enhanced Manufacturing and Quality Control 100
6.3.1.3 Smarter Commercialization and Regulatory Strategy 101
6.3.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOSIMILARS MARKET 101
6.3.3 INTERCONNECTED ADJACENT ECOSYSTEM AND
IMPACT ON MARKET PLAYERS 102
6.3.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOSIMILARS MARKET 102
6.4 SUCCESS STORIES AND REAL-WORLD APPLICATIONS 103
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 104
7.1 REGIONAL REGULATIONS AND COMPLIANCE 104
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.1.2 REGULATORY FRAMEWORK 107
7.2 REIMBURSEMENT SCENARIO ANALYSIS 109
7.2.1 INDUSTRY STANDARDS 114
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 116
7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS 117
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 118
8.1 DECISION-MAKING PROCESS 118
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 118
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 118
8.2.2 KEY BUYING CRITERIA, BY END USER 120
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 123
8.5 MARKET PROFITABILITY 124
9 BIOSIMILARS MARKET, BY DRUG CLASS 125
9.1 INTRODUCTION 126
9.2 MONOCLONAL ANTIBODIES 126
9.2.1 RITUXIMAB 131
9.2.1.1 Increasing cancer and autoimmune disease burden, coupled with expanding biosimilar competition, to support market growth 131
9.2.2 INFLIXIMAB 134
9.2.2.1 Loss of patent exclusivity to fuel adoption of Infliximab for treating autoimmune diseases 134
9.2.3 ADALIMUMAB 137
9.2.3.1 Cost-effectiveness and improved patient access to fuel segment growth 137
9.2.4 TRASTUZUMAB 140
9.2.4.1 Rising incidence of breast cancer to support market growth 140
9.2.5 PEMBROLIZUMAB 143
9.2.5.1 High-value oncology opportunity driven by Keytruda’s patent expiry and strong biosimilar pipeline 143
9.2.6 DUPILUMAB 146
9.2.6.1 Broad indication base and blockbuster sales make dupilumab high-value next-wave biosimilar opportunity 146
9.2.7 USTEKINUMAB 149
9.2.7.1 Highly competitive biosimilars market, with multiple products commercialized across major regions 149
9.2.8 RISANKIZUMAB 151
9.2.8.1 Rapidly growing Skyrizi sales and broad inflammatory-disease footprint make risankizumab major future biosimilar opportunity 151
9.2.9 DARATUMUMAB 154
9.2.9.1 High-value oncology franchise and expanding multiple myeloma use make daratumumab major future biosimilar opportunity 154
9.2.10 NIVOLUMAB 157
9.2.10.1 Large oncology revenue base and broad tumor coverage make nivolumab important future checkpoint 157
9.2.11 OTHER MONOCLONAL ANTIBODIES 159
9.3 GRANULOCYTE COLONY-STIMULATING FACTOR 164
9.3.1 MATURE COMMERCIALIZATION AND ESTABLISHED BIOSIMILAR ADOPTION MAKE G-CSF HIGH-VOLUME, PRICE-COMPETITIVE BIOSIMILAR SEGMENT 164
9.4 INSULIN 168
9.4.1 HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH 168
9.5 ERYTHROPOIETIN 171
9.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH 171
9.6 RECOMBINANT HUMAN GROWTH HORMONE 175
9.6.1 RISING INCIDENCE OF GROWTH DEFICIENCY DISORDERS IN ADULTS AND CHILDREN TO PROPEL MARKET GROWTH 175
9.7 ETANERCEPT 178
9.7.1 APPROVAL AND COMMERCIALIZATION OF ETANERCEPT BIOSIMILARS TO ACCELERATE MARKET EXPANSION 178
9.8 FOLLITROPIN 181
9.8.1 POPULARITY OF FOLLITROPIN IN INFERTILITY TREATMENT TO
SPUR MARKET GROWTH 181
9.9 TERIPARATIDE 184
9.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND 184
9.10 INTERFERONS 187
9.10.1 GROWING PREVALENCE OF INFECTIOUS DISEASES
TO SUPPORT MARKET GROWTH 187
9.11 ANTICOAGULANTS 191
9.11.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES
TO FUEL MARKET GROWTH 191
9.12 AFLIBERCEPT 194
9.12.1 LARGE OPHTHALMOLOGY MARKET AND RAPID BIOSIMILAR UPTAKE ARE MAKING AFLIBERCEPT KEY COMMERCIAL BIOSIMILAR SEGMENT 194
9.13 GLP-1 AGONIST 198
9.13.1 HIGH PREVALENCE OF DIABETES AND OBESITY TO AID MARKET GROWTH 198
9.14 OTHER DRUG CLASSES 202
10 BIOSIMILARS MARKET, BY INDICATION 205
10.1 INTRODUCTION 206
10.2 ONCOLOGY 206
10.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS FOR CANCER TO DRIVE MARKET 206
10.3 INFLAMMATORY & AUTOIMMUNE DISEASES 210
10.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS LEAD TO INCREASING INCIDENCES OF INFLAMMATORY AND AUTOIMMUNE DISEASES 210
10.4 CHRONIC DISEASES 213
10.4.1 HIGH BURDEN OF CVD WORLDWIDE TO DRIVE MARKET GROWTH 213
10.5 BLOOD DISORDERS 217
10.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND 217
10.6 GROWTH HORMONE DEFICIENCY 220
10.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT OF GHD 220
10.7 INFECTIOUS DISEASES 224
10.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC 224
10.8 TYPE II DIABETES 227
10.8.1 RISING PREVALENCE OF DIABETES PROPELS MARKET GROWTH 227
10.9 OBESITY 231
10.9.1 DEVELOPMENT OF GLP-1 ANTAGONIST BIOSIMILARS PROPELS MARKET GROWTH 231
10.10 OTHER INDICATIONS 234
11 BIOSIMILARS MARKET, BY REGION 238
11.1 INTRODUCTION 239
11.2 NORTH AMERICA 239
11.2.1 US 242
11.2.1.1 US to dominate North American biosimilars market 242
11.2.2 CANADA 246
11.2.2.1 Favorable government initiatives to support market 246
11.3 EUROPE 250
11.3.1 GERMANY 256
11.3.1.1 Germany to dominate European biosimilars market 256
11.3.2 UK 258
11.3.2.1 Increasing adoption of biosimilars to boost market 258
11.3.3 FRANCE 261
11.3.3.1 Rising geriatric population to drive market growth 261
11.3.4 ITALY 263
11.3.4.1 Favorable government policies to propel adoption of biosimilars 263
11.3.5 SPAIN 266
11.3.5.1 Favorable patient incentives to promote biosimilar use 266
11.3.6 REST OF EUROPE 269
11.4 ASIA PACIFIC 271
11.4.1 CHINA 274
11.4.1.1 China to register fastest growth in Asia Pacific market 274
11.4.2 JAPAN 277
11.4.2.1 Large geriatric population to drive market growth 277
11.4.3 INDIA 280
11.4.3.1 Increasing biosimilar launches and approvals to support market growth 280
11.4.4 SOUTH KOREA 283
11.4.4.1 Favorable government initiatives to support growth 283
11.4.5 AUSTRALIA 285
11.4.5.1 Favorable regulatory changes and increasing disease incidence to propel growth 285
11.4.6 REST OF ASIA PACIFIC 288
11.5 LATIN AMERICA 290
11.5.1 BRAZIL 293
11.5.1.1 Increased government investments in pharmaceutical
R&D to drive market 293
11.5.2 MEXICO 296
11.5.2.1 Rising demand for chronic disease treatment to support market growth 296
11.5.3 REST OF LATIN AMERICA 299
11.6 MIDDLE EAST 301
11.6.1 GCC COUNTRIES 304
11.6.1.1 Saudi Arabia 307
11.6.1.1.1 Centralized procurement, localization policies, and increasingly biosimilar-supportive regulatory framework to accelerate biosimilar adoption in Saudi Arabia 307
11.6.1.2 UAE 309
11.6.1.2.1 Rapid expansion of advanced healthcare infrastructure combined with payer pressure to reduce biologic treatment costs is strengthening commercial case for biosimilars in UAE 309
11.6.1.3 Rest of GCC 311
11.6.2 REST OF MIDDLE EAST 313
11.7 AFRICA 315
12 COMPETITIVE LANDSCAPE 317
12.1 OVERVIEW 317
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 317
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET, 2024−2026 317
12.3 REVENUE ANALYSIS, 2023-2025 319
12.4 MARKET SHARE ANALYSIS, 2025 320
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 322
12.5.1 STARS 323
12.5.2 EMERGING LEADERS 323
12.5.3 PERVASIVE PLAYERS 323
12.5.4 PARTICIPANTS 323
12.6 COMPETITIVE BENCHMARKING OF TOP PLAYERS 325
12.6.1 COMPANY FOOTPRINT 325
12.6.2 REGION FOOTPRINT 326
12.6.3 DRUG CLASS FOOTPRINT 327
12.6.4 INDICATION FOOTPRINT 328
12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 329
12.7.1 PROGRESSIVE COMPANIES 329
12.7.2 RESPONSIVE COMPANIES 329
12.7.3 DYNAMIC COMPANIES 329
12.7.4 STARTING BLOCKS 329
12.8 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 331
12.9 VALUATION AND FINANCIAL METRICS OF BIOSIMILAR VENDORS 333
12.9.1 FINANCIAL METRICS 333
12.9.2 COMPANY VALUATION 333
12.10 BRAND/PRODUCT COMPARISON 334
12.11 COMPETITIVE SCENARIO 335
12.11.1 PRODUCT APPROVALS 335
12.11.2 DEALS 336
12.11.3 EXPANSIONS 337
13 COMPANY PROFILES 338
13.1 KEY PLAYERS 338
13.1.1 SANDOZ GROUP AG 338
13.1.1.1 Products offered 340
13.1.1.2 Products in pipeline 340
13.1.1.3 Recent developments 341
13.1.1.3.1 Product launches and approvals 341
13.1.1.3.2 Deals 342
13.1.1.3.3 Expansions 343
13.1.1.3.4 Other developments 343
13.1.1.4 MnM view 343
13.1.1.4.1 Key strengths 343
13.1.1.4.2 Strategic choices 343
13.1.1.4.3 Weaknesses & competitive threats 344
13.1.2 AMGEN INC. 345
13.1.2.1 Products offered 347
13.1.2.2 Products in pipeline 347
13.1.2.3 Recent developments 348
13.1.2.3.1 Product launches and approvals 348
13.1.2.3.2 Deals 348
13.1.2.3.3 Expansions 349
13.1.2.4 MnM view 349
13.1.2.4.1 Key strengths 349
13.1.2.4.2 Strategic choices 350
13.1.2.4.3 Weaknesses & competitive threats 350
13.1.3 CELLTRION INC. 351
13.1.3.1 Products offered 353
13.1.3.2 Recent developments 354
13.1.3.2.1 Product launches and approvals 354
13.1.3.2.2 Deals 355
13.1.3.2.3 Expansions 355
13.1.3.3 MnM view 356
13.1.3.3.1 Key strengths 356
13.1.3.3.2 Strategic choices 356
13.1.3.3.3 Weaknesses & competitive threats 356
13.1.4 PFIZER INC. 357
13.1.4.1 Business overview 357
13.1.4.2 Products offered 358
13.1.4.3 Recent developments 359
13.1.4.3.1 Product approvals 359
13.1.4.3.2 Deals 360
13.1.4.4 MnM view 360
13.1.4.4.1 Key strengths 360
13.1.4.4.2 Strategic choices 360
13.1.4.4.3 Weaknesses & competitive threats 361
13.1.5 BIOCON 362
13.1.5.1 Business overview 362
13.1.5.2 Products offered 364
13.1.5.3 Recent developments 365
13.1.5.3.1 Product approvals 365
13.1.5.3.2 Deals 366
13.1.5.3.3 Other developments 366
13.1.5.4 MnM view 367
13.1.5.4.1 Key strengths 367
13.1.5.4.2 Strategic choices 367
13.1.5.4.3 Weaknesses & competitive threats 367
13.1.6 DR. REDDY’S LABORATORIES LTD. 368
13.1.6.1 Products offered 369
13.1.6.2 Recent developments 370
13.1.6.2.1 Product launches 370
13.1.6.2.2 Deals 370
13.1.6.2.3 Other developments 371
13.1.7 ELI LILLY AND COMPANY 372
13.1.7.1 Products offered 373
13.1.7.2 Recent developments 374
13.1.7.2.1 Product launches 374
13.1.7.2.2 Deals 374
13.1.7.2.3 Expansions 374
13.1.8 TEVA PHARMACEUTICAL INDUSTRIES LTD. 375
13.1.8.1 Products offered 376
13.1.8.2 Recent developments 376
13.1.8.2.1 Product launches and approvals 376
13.1.8.2.2 Deals 377
13.1.8.2.3 Other developments 378
13.1.9 FRESENIUS KABI AG 379
13.1.9.1 Products offered 380
13.1.9.2 Recent developments 381
13.1.9.2.1 Product Launches and Approvals 381
13.1.9.2.2 Deals 382
13.1.9.2.3 Other developments 382
13.1.10 STADA ARZNEIMITTEL AG 383
13.1.10.1 Products offered 384
13.1.10.2 Recent developments 385
13.1.10.2.1 Product launches/Approvals 385
13.1.10.2.2 Deals 386
13.1.10.2.3 Expansions 387
13.1.10.2.4 Other developments 387
13.1.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 388
13.1.11.1 Products offered 389
13.1.11.2 Recent developments 390
13.1.11.2.1 Product approvals 390
13.1.11.2.2 Deals 390
13.1.11.2.3 Expansions 390
13.1.12 SAMSUNG BIOEPIS HOLDINGS CO., LTD. 391
13.1.12.1 Business overview 391
13.1.12.2 Products offered 392
13.1.12.3 Recent developments 394
13.1.12.3.1 Product Launches and Approvals 394
13.1.12.3.2 Deals 395
13.1.13 AMNEAL PHARMACEUTICALS LLC 396
13.1.13.1 Business overview 396
13.1.13.2 Products offered 397
13.1.13.3 Recent developments 397
13.1.13.3.1 Product approvals 397
13.1.13.3.2 Deals 398
13.1.13.3.3 Other developments 398
13.1.14 BIO THERA SOLUTIONS 399
13.1.14.1 Business overview 399
13.1.14.2 Products offered 400
13.1.14.3 Recent developments 400
13.1.14.3.1 Product approvals 400
13.1.14.3.2 Deals 401
13.1.15 APROGEN 402
13.1.15.1 Business overview 402
13.1.15.2 Products offered 402
13.1.15.3 Recent developments 402
13.1.15.3.1 Product approvals 402
13.1.15.4 Products in pipeline 403
13.1.16 SHANGHAI HENLIUS BIOTECH, INC. 404
13.1.16.1 Business overview 404
13.1.16.2 Products offered 405
13.1.16.3 Products in pipeline 405
13.1.16.4 Recent developments 406
13.1.16.4.1 Product approvals 406
13.1.16.4.2 Deals 406
13.1.16.4.3 Other developments 407
13.1.17 ALVOTECH 408
13.1.17.1 Business overview 408
13.1.17.2 Products offered 409
13.1.17.3 Products in pipeline 410
13.1.17.4 Recent developments 410
13.1.17.4.1 Product approvals 410
13.1.17.4.2 Deals 411
13.2 OTHER PLAYERS 413
13.2.1 AMEGA BIOTECH 413
13.2.2 BIOCAD 414
13.2.3 PROBIOMED S.A. DE C.V. 414
13.2.4 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD. 415
13.2.5 POLPHARMA BIOLOGICS GROUP 416
13.2.6 NEUCLONE 417
13.2.7 XENTRIA 418
13.2.8 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC 419
13.2.9 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD. 420
13.2.10 CURATEQ BIOLOGICS PVT. LTD. 421
13.2.11 XBRANE BIOPHARMA AB 422
13.2.12 FORMYCON AG 423
13.2.13 SAM CHUN DANG PHARM. CO., LTD. 424
13.2.14 PRESTIGE BIOPHARMA 425
13.2.15 BIOEQ AG 426
14 RESEARCH METHODOLOGY 427
14.1 RESEARCH DATA 427
14.1.1 SECONDARY DATA 428
14.1.1.1 Key data from secondary sources 429
14.1.2 PRIMARY DATA 429
14.2 MARKET ESTIMATION METHODOLOGY 431
14.2.1 GLOBAL MARKET ESTIMATION 431
14.2.2 INSIGHTS OF PRIMARY EXPERTS 433
14.2.3 SEGMENTAL MARKET SIZE ESTIMATION 434
14.3 MARKET GROWTH RATE PROJECTIONS 435
14.4 MARKET BREAKDOWN AND DATA TRIANGULATION 436
14.5 RESEARCH ASSUMPTIONS 437
14.6 RESEARCH LIMITATIONS 438
14.7 RISK ANALYSIS 438
15 APPENDIX 439
15.1 DISCUSSION GUIDE 439
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 443
15.3 CUSTOMIZATION OPTIONS 445
15.4 RELATED REPORTS 446
15.5 AUTHOR DETAILS 447
圖表清單 List of Tables & Figures
TABLE 1 BIOSIMILARS MARKET: INCLUSIONS AND EXCLUSIONS 38
TABLE 2 BIOSIMILARS MARKET: IMPACT ANALYSIS 53
TABLE 3 BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION,
2023–2030 (USD MILLION) 62
TABLE 4 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS 66
TABLE 5 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 69
TABLE 6 BIOSIMILARS MARKET: ROLE IN ECOSYSTEM 74
TABLE 7 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,
BY KEY PLAYER, 2023–2025 (USD) 76
TABLE 8 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION,
2023–2025 (USD) 78
TABLE 9 BIOSIMILARS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 79
TABLE 10 PORTFOLIO SCALE & COMMERCIALIZATION 82
TABLE 11 PAYER ACCESS & MARKET PENETRATION 83
TABLE 12 PRODUCT DIFFERENTIATION & INTERCHANGEABILITY 83
TABLE 13 US ADJUSTED RECIPROCAL TARIFF RATES 84
TABLE 14 BIOSIMILARS MARKET: PRODUCTS IN CLINICAL PIPELINE 88
TABLE 15 BIOSIMILARS MARKET: LIST OF KEY BIOLOGICS TO GO OFF-PATENT, 2026–2036 89
TABLE 16 BIOSIMILARS MARKET: LIST OF BIOSIMILARS MANUFACTURING FACILITIES
(IN-HOUSE) BY KEY PLAYER 91
TABLE 17 BIOSIMILARS MARKET: LIST OF KEY MANUFACTURING FACILITY EXPANSION 93
TABLE 18 KEY COMPANIES TECHNOLOGY/PRODUCT ROADMAP — BIOSIMILARS MARKET 98
TABLE 19 CASE STUDIES OF AI IMPLEMENTATION IN BIOSIMILARS MARKET 101
TABLE 20 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN BIOSIMILARS MARKET 103
TABLE 21 KEY SUCCESS STORIES WITH RESPECT OT REAL WORLD APPLICATION IN BIOSIMILARS MARKET 103
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 105
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 105
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 26 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REGULATORY FRAMEWORK 107
TABLE 27 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REIMBURSEMENT FRAMEWORK 110
TABLE 28 US: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHED BIOSIMILARS,
2025–2026 111
TABLE 29 US: REIMBURSEMENT CODES FOR BIOSIMILAR PRODUCTS 112
TABLE 30 EUROPE: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHED
BIOSIMILARS, 2025–2026 113
TABLE 31 KEY INDUSTRY STANDARDS FOR BIOSIMILARS MARKET 115
TABLE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS (%) 119
TABLE 33 KEY BUYING CRITERIA, BY END USER 120
TABLE 34 UNMET NEEDS ACROSS DIFFERENT END USERS IN BIOSIMILARS MARKET 123
TABLE 35 BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 126
TABLE 36 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 127
TABLE 37 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,
2024–2036 (USD MILLION) 128
TABLE 38 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2036 (USD MILLION) 128
TABLE 39 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2036 (USD MILLION) 129
TABLE 40 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2036 (USD MILLION) 129
TABLE 41 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2036 (USD MILLION) 130
TABLE 42 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2024–2036 (USD MILLION) 130
TABLE 43 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2024–2036 (USD MILLION) 130
TABLE 44 RITUXIMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 131
TABLE 45 NORTH AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 132
TABLE 46 EUROPE: RITUXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 132
TABLE 47 ASIA PACIFIC: RITUXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 132
TABLE 48 LATIN AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 133
TABLE 49 MIDDLE EAST: RITUXIMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 133
TABLE 50 GCC COUNTRIES: RITUXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 133
TABLE 51 INFLIXIMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 134
TABLE 52 NORTH AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 135
TABLE 53 EUROPE: INFLIXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 135
TABLE 54 ASIA PACIFIC: INFLIXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 135
TABLE 55 LATIN AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 136
TABLE 56 MIDDLE EAST: INFLIXIMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 136
TABLE 57 GCC COUNTRIES: INFLIXIMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 136
TABLE 58 ADALIMUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 137
TABLE 59 NORTH AMERICA: ADALIMUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 138
TABLE 60 EUROPE: ADALIMUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 138
TABLE 61 ASIA PACIFIC: ADALIMUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 138
TABLE 62 LATIN AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 139
TABLE 63 MIDDLE EAST: ADALIMUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 139
TABLE 64 GCC COUNTRIES: ADALIMUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 139
TABLE 65 TRASTUZUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 140
TABLE 66 NORTH AMERICA: TRASTUZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 141
TABLE 67 EUROPE: TRASTUZUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 141
TABLE 68 ASIA PACIFIC: TRASTUZUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 141
TABLE 69 LATIN AMERICA: TRASTUZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 142
TABLE 70 MIDDLE EAST: TRASTUZUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 142
TABLE 71 GCC COUNTRIES: TRASTUZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 142
TABLE 72 PEMBROLIZUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 143
TABLE 73 NORTH AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 144
TABLE 74 EUROPE: PEMBROLIZUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 144
TABLE 75 ASIA PACIFIC: PEMBROLIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 144
TABLE 76 LATIN AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 145
TABLE 77 MIDDLE EAST: PEMBROLIZUMAB MARKET, BY REGION,
2024–2036 (USD MILLION) 145
TABLE 78 GCC COUNTRIES: PEMBROLIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 145
TABLE 79 DUPILUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 146
TABLE 80 NORTH AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 147
TABLE 81 EUROPE: DUPILUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 147
TABLE 82 ASIA PACIFIC: DUPILUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 147
TABLE 83 LATIN AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 148
TABLE 84 MIDDLE EAST: DUPILUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 148
TABLE 85 GCC COUNTRIES: DUPILUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 148
TABLE 86 USTEKINUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 149
TABLE 87 NORTH AMERICA: USTEKINUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 149
TABLE 88 EUROPE: USTEKINUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 150
TABLE 89 ASIA PACIFIC: USTEKINUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 150
TABLE 90 LATIN AMERICA: USTEKINUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 150
TABLE 91 MIDDLE EAST: USTEKINUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 151
TABLE 92 GCC COUNTRIES: USTEKINUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 151
TABLE 93 RISANKIZUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 152
TABLE 94 NORTH AMERICA: RISANKIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 152
TABLE 95 EUROPE: RISANKIZUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 152
TABLE 96 ASIA PACIFIC: RISANKIZUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 153
TABLE 97 LATIN AMERICA: RISANKIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 153
TABLE 98 MIDDLE EAST: RISANKIZUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 153
TABLE 99 GCC COUNTRIES: RISANKIZUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 154
TABLE 100 DARATUMUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 154
TABLE 101 NORTH AMERICA: DARATUMUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 155
TABLE 102 EUROPE: DARATUMUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 155
TABLE 103 ASIA PACIFIC: DARATUMUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 155
TABLE 104 LATIN AMERICA: DARATUMUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 156
TABLE 105 MIDDLE EAST: DARATUMUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 156
TABLE 106 GCC COUNTRIES: DARATUMUMAB MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 156
TABLE 107 NIVOLUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 157
TABLE 108 NORTH AMERICA: NIVOLUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 157
TABLE 109 EUROPE: NIVOLUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 158
TABLE 110 ASIA PACIFIC: NIVOLUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 158
TABLE 111 LATIN AMERICA: NIVOLUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 158
TABLE 112 MIDDLE EAST: NIVOLUMAB MARKET, BY REGION, 2024–2036 (USD MILLION) 159
TABLE 113 GCC COUNTRIES: NIVOLUMAB MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 159
TABLE 114 OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION,
2024–2036 (USD MILLION) 161
TABLE 115 NORTH AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET,
BY COUNTRY, 2024–2036 (USD MILLION) 161
TABLE 116 EUROPE: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 162
TABLE 117 ASIA PACIFIC: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 162
TABLE 118 LATIN AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 163
TABLE 119 MIDDLE EAST: OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION,
2024–2036 (USD MILLION) 163
TABLE 120 GCC COUNTRIES: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 163
TABLE 121 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) 164
TABLE 122 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,
BY REGION, 2024–2036 (USD MILLION) 165
TABLE 123 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024–2036 (USD MILLION) 165
TABLE 124 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024–2036 (USD MILLION) 166
TABLE 125 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024–2036 (USD MILLION) 166
TABLE 126 LATIN AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024–2036 (USD MILLION) 167
TABLE 127 MIDDLE EAST: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024–2036 (USD MILLION) 167
TABLE 128 GCC COUNTRIES: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2024–2036 (USD MILLION) 167
TABLE 129 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2024–2036 (USD MILLION) 168
TABLE 130 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2024–2036 (USD MILLION) 169
TABLE 131 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2024–2036 (USD MILLION) 169
TABLE 132 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2024–2036 (USD MILLION) 170
TABLE 133 LATIN AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2024–2036 (USD MILLION) 170
TABLE 134 MIDDLE EAST: BIOSIMILARS MARKET FOR INSULIN, BY REGION,
2024–2036 (USD MILLION) 170
TABLE 135 GCC COUNTRIES: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2024–2036 (USD MILLION) 171
TABLE 136 LIST OF KEY APPROVED BIOSIMILARS FOR ERYTHROPOIETIN 171
TABLE 137 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2024–2036 (USD MILLION) 172
TABLE 138 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN,
BY COUNTRY, 2024–2036 (USD MILLION) 172
TABLE 139 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY,
2024–2036 (USD MILLION) 173
TABLE 140 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY,
2024–2036 (USD MILLION) 173
TABLE 141 LATIN AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2036 (USD MILLION) 174
TABLE 142 MIDDLE EAST: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2024–2036 (USD MILLION) 174
TABLE 143 GCC COUNTRIES: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024–2036 (USD MILLION) 174
TABLE 144 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,
BY REGION, 2024–2036 (USD MILLION) 175
TABLE 145 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024–2036 (USD MILLION) 176
TABLE 146 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024–2036 (USD MILLION) 176
TABLE 147 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024–2036 (USD MILLION) 177
TABLE 148 LATIN AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024–2036 (USD MILLION) 177
TABLE 149 MIDDLE EAST: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2024–2036 (USD MILLION) 177
TABLE 150 GCC COUNTRIES: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2024–2036 (USD MILLION) 178
TABLE 151 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2024–2036 (USD MILLION) 178
TABLE 152 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 179
TABLE 153 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 179
TABLE 154 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 180
TABLE 155 LATIN AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 180
TABLE 156 MIDDLE EAST: BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION,
2024–2036 (USD MILLION) 180
TABLE 157 GCC COUNTRIES: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 181
TABLE 158 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2024–2036 (USD MILLION) 181
TABLE 159 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2024–2036 (USD MILLION) 182
TABLE 160 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2024–2036 (USD MILLION) 182
TABLE 161 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2024–2036 (USD MILLION) 183
TABLE 162 LATIN AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2024–2036 (USD MILLION) 183
TABLE 163 MIDDLE EAST: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION,
2024–2036 (USD MILLION) 183
TABLE 164 GCC COUNTRIES: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2024–2036 (USD MILLION) 184
TABLE 165 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,
2024–2036 (USD MILLION) 184
TABLE 166 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2024–2036 (USD MILLION) 185
TABLE 167 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2024–2036 (USD MILLION) 185
TABLE 168 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2024–2036 (USD MILLION) 186
TABLE 169 LATIN AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2024–2036 (USD MILLION) 186
TABLE 170 MIDDLE EAST: BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,
2024–2036 (USD MILLION) 186
TABLE 171 GCC COUNTRIES: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2024–2036 (USD MILLION) 187
TABLE 172 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2024–2036 (USD MILLION) 188
TABLE 173 NORTH AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2024–2036 (USD MILLION) 188
TABLE 174 EUROPE: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2024–2036 (USD MILLION) 189
TABLE 175 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2024–2036 (USD MILLION) 189
TABLE 176 LATIN AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2024–2036 (USD MILLION) 190
TABLE 177 MIDDLE EAST: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2024–2036 (USD MILLION) 190
TABLE 178 GCC COUNTRIES: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2024–2036 (USD MILLION) 190
TABLE 179 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION,
2024–2036 (USD MILLION) 191
TABLE 180 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2024–2036 (USD MILLION) 192
TABLE 181 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY,
2024–2036 (USD MILLION) 192
TABLE 182 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY,
2024–2036 (USD MILLION) 193
TABLE 183 LATIN AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2024–2036 (USD MILLION) 193
TABLE 184 MIDDLE EAST: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION,
2024–2036 (USD MILLION) 193
TABLE 185 GCC COUNTRIES: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2024–2036 (USD MILLION) 194
TABLE 186 BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 2024–2036 (USD MILLION) 195
TABLE 187 NORTH AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 195
TABLE 188 EUROPE: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 196
TABLE 189 ASIA PACIFIC: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 196
TABLE 190 LATIN AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 197
TABLE 191 MIDDLE EAST: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION,
2024–2036 (USD MILLION) 197
TABLE 192 GCC COUNTRIES: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2024–2036 (USD MILLION) 197
TABLE 193 BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY REGION,
2024–2036 (USD MILLION) 199
TABLE 194 NORTH AMERICA: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY, 2024–2036 (USD MILLION) 199
TABLE 195 EUROPE: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY,
2024–2036 (USD MILLION) 200
TABLE 196 ASIA PACIFIC: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY,
2024–2036 (USD MILLION) 200
TABLE 197 LATIN AMERICA: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY,
2024–2036 (USD MILLION) 201
TABLE 198 MIDDLE EAST: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY REGION,
2024–2036 (USD MILLION) 201
TABLE 199 GCC COUNTRIES: BIOSIMILARS MARKET FOR GLP-1 AGONIST, BY COUNTRY, 2024–2036 (USD MILLION) 201
TABLE 200 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION,
2024–2036 (USD MILLION) 202
TABLE 201 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES,
BY COUNTRY, 2024–2036 (USD MILLION) 202
TABLE 202 EUROPE: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2024–2036 (USD MILLION) 203
TABLE 203 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2024–2036 (USD MILLION) 203
TABLE 204 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2024–2036 (USD MILLION) 204
TABLE 205 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2024–2036 (USD MILLION) 204
TABLE 206 GCC COUNTRIES: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES,
BY COUNTRY, 2024–2036 (USD MILLION) 204
TABLE 207 BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 206
TABLE 208 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2024–2036 (USD MILLION) 207
TABLE 209 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2036 (USD MILLION) 207
TABLE 210 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2036 (USD MILLION) 208
TABLE 211 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2036 (USD MILLION) 208
TABLE 212 LATIN AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2036 (USD MILLION) 209
TABLE 213 MIDDLE EAST: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION,
2024–2036 (USD MILLION) 209
TABLE 214 GCC COUNTRIES: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2024–2036 (USD MILLION) 209
TABLE 215 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES,
BY REGION, 2024–2036 (USD MILLION) 210
TABLE 216 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 211
TABLE 217 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 211
TABLE 218 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 212
TABLE 219 LATIN AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 212
TABLE 220 MIDDLE EAST: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2024–2036 (USD MILLION) 212
TABLE 221 GCC COUNTRIES: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 213
TABLE 222 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2024–2036 (USD MILLION) 214
TABLE 223 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES,
BY COUNTRY, 2024–2036 (USD MILLION) 214
TABLE 224 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY,
2024–2036 (USD MILLION) 215
TABLE 225 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 215
TABLE 226 LATIN AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 216
TABLE 227 MIDDLE EAST: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2024–2036 (USD MILLION) 216
TABLE 228 GCC COUNTRIES: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 216
TABLE 229 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2024–2036 (USD MILLION) 217
TABLE 230 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024–2036 (USD MILLION) 218
TABLE 231 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY,
2024–2036 (USD MILLION) 218
TABLE 232 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024–2036 (USD MILLION) 219
TABLE 233 LATIN AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024–2036 (USD MILLION) 219
TABLE 234 MIDDLE EAST: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2024–2036 (USD MILLION) 219
TABLE 235 GCC COUNTRIES: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2024–2036 (USD MILLION) 220
TABLE 236 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION,
2024–2036 (USD MILLION) 221
TABLE 237 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2024–2036 (USD MILLION) 221
TABLE 238 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2024–2036 (USD MILLION) 222
TABLE 239 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2024–2036 (USD MILLION) 222
TABLE 240 LATIN AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2024–2036 (USD MILLION) 223
TABLE 241 MIDDLE EAST: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY REGION, 2024–2036 (USD MILLION) 223
TABLE 242 GCC COUNTRIES: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2024–2036 (USD MILLION) 223
TABLE 243 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2036 (USD MILLION) 224
TABLE 244 NORTH AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2024–2036 (USD MILLION) 225
TABLE 245 EUROPE: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2024–2036 (USD MILLION) 225
TABLE 246 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 226
TABLE 247 LATIN AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 226
TABLE 248 MIDDLE EAST: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2036 (USD MILLION) 226
TABLE 249 GCC COUNTRIES: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2036 (USD MILLION) 227
TABLE 250 BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION,
2024–2036 (USD MILLION) 228
TABLE 251 NORTH AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES,
BY COUNTRY, 2024–2036 (USD MILLION) 228
TABLE 252 EUROPE: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY,
2024–2036 (USD MILLION) 229
TABLE 253 ASIA PACIFIC: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY,
2024–2036 (USD MILLION) 229
TABLE 254 LATIN AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2024–2036 (USD MILLION) 230
TABLE 255 MIDDLE EAST: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION,
2024–2036 (USD MILLION) 230
TABLE 256 GCC COUNTRIES: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2024–2036 (USD MILLION) 230
TABLE 257 BIOSIMILARS MARKET FOR OBESITY, BY REGION, 2024–2036 (USD MILLION) 231
TABLE 258 NORTH AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2024–2036 (USD MILLION) 232
TABLE 259 EUROPE: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2024–2036 (USD MILLION) 232
TABLE 260 ASIA PACIFIC: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2024–2036 (USD MILLION) 233
TABLE 261 LATIN AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2024–2036 (USD MILLION) 233
TABLE 262 MIDDLE EAST: BIOSIMILARS MARKET FOR OBESITY, BY REGION,
2024–2036 (USD MILLION) 233
TABLE 263 GCC COUNTRIES: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2024–2036 (USD MILLION) 234
TABLE 264 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION,
2024–2036 (USD MILLION) 235
TABLE 265 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2036 (USD MILLION) 235
TABLE 266 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY,
2024–2036 (USD MILLION) 236
TABLE 267 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2036 (USD MILLION) 236
TABLE 268 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2036 (USD MILLION) 237
TABLE 269 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2036 (USD MILLION) 237
TABLE 270 GCC COUNTRIES: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2036 (USD MILLION) 237
TABLE 271 BIOSIMILARS MARKET, BY REGION, 2024–2036 (USD MILLION) 239
TABLE 272 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 240
TABLE 273 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 240
TABLE 274 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2024–2036 (USD MILLION) 241
TABLE 275 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 241
TABLE 276 US: LIST OF APPROVED BIOSIMILARS (2023-2026) 242
TABLE 277 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 244
TABLE 278 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 245
TABLE 279 US: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 245
TABLE 280 CANADA: LIST OF APPROVED BIOSIMILARS (2023-2026) 246
TABLE 281 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 248
TABLE 282 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 249
TABLE 283 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 249
TABLE 284 EUROPE: LIST OF APPROVED BIOSIMILARS (2023-2026) 251
TABLE 285 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 254
TABLE 286 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 254
TABLE 287 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 255
TABLE 288 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 255
TABLE 289 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 256
TABLE 290 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 257
TABLE 291 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 257
TABLE 292 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 259
TABLE 293 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 260
TABLE 294 UK: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 260
TABLE 295 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 261
TABLE 296 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 262
TABLE 297 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 262
TABLE 298 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 264
TABLE 299 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 265
TABLE 300 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 265
TABLE 301 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 267
TABLE 302 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 268
TABLE 303 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 268
TABLE 304 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 269
TABLE 305 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2024–2036 (USD MILLION) 270
TABLE 306 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 270
TABLE 307 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 271
TABLE 308 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 272
TABLE 309 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2024–2036 (USD MILLION) 273
TABLE 310 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 273
TABLE 311 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 275
TABLE 312 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 276
TABLE 313 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 276
TABLE 314 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 278
TABLE 315 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 279
TABLE 316 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 279
TABLE 317 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 281
TABLE 318 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 282
TABLE 319 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 282
TABLE 320 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 283
TABLE 321 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2024–2036 (USD MILLION) 284
TABLE 322 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 284
TABLE 323 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 286
TABLE 324 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 287
TABLE 325 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 287
TABLE 326 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 288
TABLE 327 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2024–2036 (USD MILLION) 289
TABLE 328 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 289
TABLE 329 LATIN AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2024–2036 (USD MILLION) 290
TABLE 330 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 291
TABLE 331 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 292
TABLE 332 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 292
TABLE 333 BRAZIL: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 294
TABLE 334 BRAZIL: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 295
TABLE 335 BRAZIL: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 295
TABLE 336 MEXICO: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 297
TABLE 337 MEXICO: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 298
TABLE 338 MEXICO: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 298
TABLE 339 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 299
TABLE 340 REST OF LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 300
TABLE 341 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 300
TABLE 342 MIDDLE EAST: BIOSIMILARS MARKET, BY REGION, 2024–2036 (USD MILLION) 302
TABLE 343 MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 302
TABLE 344 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 303
TABLE 345 MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 303
TABLE 346 GCC COUNTRIES: BIOSIMILARS MARKET, BY COUNTRY,
2024–2036 (USD MILLION) 304
TABLE 347 GCC COUNTRIES: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 305
TABLE 348 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 306
TABLE 349 GCC COUNTRIES: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 306
TABLE 350 SAUDI ARABIA: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 307
TABLE 351 SAUDI ARABIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 308
TABLE 352 SAUDI ARABIA: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 308
TABLE 353 UAE: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 309
TABLE 354 UAE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 310
TABLE 355 UAE: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 310
TABLE 356 REST OF GCC: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 311
TABLE 357 REST OF GCC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2024–2036 (USD MILLION) 312
TABLE 358 REST OF GCC: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 312
TABLE 359 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS,
2024–2036 (USD MILLION) 313
TABLE 360 REST OF MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2024–2036 (USD MILLION) 314
TABLE 361 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION,
2024–2036 (USD MILLION) 314
TABLE 362 AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2024–2036 (USD MILLION) 315
TABLE 363 AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2024–2036 (USD MILLION) 316
TABLE 364 AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2024–2036 (USD MILLION) 316
TABLE 365 STRATEGIES DEPLOYED BY KEY PLAYERS 317
TABLE 366 BIOSIMILARS MARKET: DEGREE OF COMPETITION 321
TABLE 367 BIOSIMILARS MARKET: REGIONAL FOOTPRINT 326
TABLE 368 BIOSIMILARS MARKET: DRUG CLASS FOOTPRINT 327
TABLE 369 BIOSIMILARS MARKET: INDICATION FOOTPRINT 328
TABLE 370 BIOSIMILARS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 331
TABLE 371 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, 2025 332
TABLE 372 BIOSIMILARS MARKET: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 335
TABLE 373 BIOSIMILARS MARKET: DEALS, JANUARY 2023–AUGUST 2026 336
TABLE 374 BIOSIMILARS MARKET: EXPANSIONS, JANUARY 2023–AUGUST 2026 337
TABLE 375 SANDOZ GROUP AG: COMPANY OVERVIEW 338
TABLE 376 SANDOZ GROUP AG: PRODUCTS OFFERED 340
TABLE 377 SANDOZ GROUP AG: PRODUCTS IN PIPELINE 340
TABLE 378 SANDOZ GROUP AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–AUGUST 2026 341
TABLE 379 SANDOZ GROUP AG: DEALS, JANUARY 2023–AUGUST 2026 342
TABLE 380 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2023–AUGUST 2026 343
TABLE 381 SANDOZ GROUP AG: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 343
TABLE 382 AMGEN INC.: COMPANY OVERVIEW 345
TABLE 383 AMGEN INC.: PRODUCTS OFFERED 347
TABLE 384 AMGEN INC.: PRODUCTS IN PIPELINE 347
TABLE 385 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–AUGUST 2026 348
TABLE 386 AMGEN INC.: DEALS, JANUARY 2023–AUGUST 2026 348
TABLE 387 AMGEN INC.: EXPANSIONS, JANUARY 2023–AUGUST 2026 349
TABLE 388 CELLTRION INC.: COMPANY OVERVIEW 351
TABLE 389 CELLTRION INC.: PRODUCTS OFFERED 353
TABLE 390 CELLTRION INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–AUGUST 2026 354
TABLE 391 CELLTRION INC.: DEALS, JANUARY 2023–AUGUST 2026 355
TABLE 392 CELLTRION INC.: EXPANSIONS, JANUARY 2023–AUGUST 2026 355
TABLE 393 PFIZER INC.: COMPANY OVERVIEW 357
TABLE 394 PFIZER INC.: PRODUCTS OFFERED 358
TABLE 395 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 359
TABLE 396 PFIZER INC.: DEALS, JANUARY 2023–AUGUST 2026 360
TABLE 397 BIOCON: COMPANY OVERVIEW 362
TABLE 398 BIOCON: PRODUCTS OFFERED 364
TABLE 399 BIOCON: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 365
TABLE 400 BIOCON: DEALS, JANUARY 2023–AUGUST 2026 366
TABLE 401 BIOCON: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 366
TABLE 402 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW 368
TABLE 403 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED 369
TABLE 404 DR. REDDY’S LABORATORIES LTD.: PRODUCT LAUNCHES,
JANUARY 2023–AUGUST 2026 370
TABLE 405 DR. REDDY’S LABORATORIES LTD.: DEALS, JANUARY 2023–AUGUST 2026 370
TABLE 406 DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS,
JANUARY 2023–AUGUST 2026 371
TABLE 407 ELI LILLY AND COMPANY: COMPANY OVERVIEW 372
TABLE 408 ELI LILLY AND COMPANY: PRODUCTS OFFERED 373
TABLE 409 ELI LILLY AND COMPANY: PRODUCT LAUNCHES, JANUARY 2023–AUGUST 2026 374
TABLE 410 ELI LILLY AND COMPANY: DEALS, JANUARY 2023–AUGUST 2026 374
TABLE 411 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2023–AUGUST 2026 374
TABLE 412 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 375
TABLE 413 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 376
TABLE 414 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–AUGUST 2026 376
TABLE 415 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2023–AUGUST 2026 377
TABLE 416 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS,
JANUARY 2023–AUGUST 2026 378
TABLE 417 FRESENIUS KABI AG: COMPANY OVERVIEW 379
TABLE 418 FRESENIUS KABI AG.: PRODUCTS OFFERED 380
TABLE 419 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–AUGUST 2026 381
TABLE 420 FRESENIUS KABI AG: DEALS, JANUARY 2023–AUGUST 2026 382
TABLE 421 FRESENIUS KABI AG: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 382
TABLE 422 STADA ARZNEIMITTEL AG: COMPANY OVERVIEW 383
TABLE 423 STADA ARZNEIMITTEL AG: PRODUCTS OFFERED 384
TABLE 424 STADA ARZNEIMITTEL AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2023–AUGUST 2026 385
TABLE 425 STADA ARZNEIMITTEL AG: DEALS, JANUARY 2023–AUGUST 2026 386
TABLE 426 STADA ARZNEIMITTEL AG: EXPANSIONS, JANUARY 2023–AUGUST 2026 387
TABLE 427 STADA ARZNEIMITTEL AG: OTHER DEVELOPMENTS, JANUARY 2023–AUGUST 2026 387
TABLE 428 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 388
TABLE 429 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 389
TABLE 430 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 390
TABLE 431 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS,
JANUARY 2023–AUGUST 2026 390
TABLE 432 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS,
JANUARY 2023–AUGUST 2026 390
TABLE 433 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: COMPANY OVERVIEW 391
TABLE 434 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: PRODUCTS OFFERED 392
TABLE 435 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–AUGUST 2026 394
TABLE 436 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: DEALS, JANUARY 2023–AUGUST 2026 395
TABLE 437 AMNEAL PHARMACEUTICALS LLC: COMPANY OVERVIEW 396
TABLE 438 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED 397
TABLE 439 AMNEAL PHARMACEUTICALS LLC: PRODUCT APPROVALS,
JANUARY 2023–AUGUST 2026 397
TABLE 440 AMNEAL PHARMACEUTICALS INC: DEALS, JANUARY 2023–AUGUST 2026 398
TABLE 441 AMNEAL PHARMACEUTICALS INC: OTHER DEVELOPMENTS,
JANUARY 2023–AUGUST 2026 398
TABLE 442 BIO THERA SOLUTIONS: COMPANY OVERVIEW 399
TABLE 443 BIO THERA SOLUTIONS: PRODUCTS OFFERED 400
TABLE 444 BIO THERA SOLUTIONS: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 400
TABLE 445 BIO THERA SOLUTIONS: DEALS, JANUARY 2023–AUGUST 2026 401
TABLE 446 APROGEN: COMPANY OVERVIEW 402
TABLE 447 APROGEN: PRODUCTS OFFERED 402
TABLE 448 APROGEN: PRODUCT DEVELOPMENTS, JANUARY 2023–AUGUST 2026 402
TABLE 449 APROGEN: PRODUCTS IN PIPELINE 403
TABLE 450 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW 404
TABLE 451 SHANGHAI HENLIUS BIOTECH, INC.: PRODUCTS OFFERED 405
TABLE 452 SHANGHAI HENLIUS BIOTECH, INC.: PRODUCTS IN PIPELINE 405
TABLE 453 SHANGHAI HENLIUS BIOTECH, INC.: PRODUCT APPROVALS,
JANUARY 2023–AUGUST 2026 406
TABLE 454 SHANGHAI HENLIUS BIOTECH, INC.: DEALS, JANUARY 2023–AUGUST 2026 406
TABLE 455 SHANGHAI HENLIUS BIOTECH, INC.: OTHER DEVELOPMENTS,
JANUARY 2023–AUGUST 2026 407
TABLE 456 ALVOTECH: COMPANY OVERVIEW 408
TABLE 457 ALVOTECH: PRODUCTS OFFERED 409
TABLE 458 ALVOTECH: PRODUCTS IN PIPELINE 410
TABLE 459 ALVOTECH: PRODUCT APPROVALS, JANUARY 2023–AUGUST 2026 410
TABLE 460 ALVOTECH: DEALS, JANUARY 2023–AUGUST 2026 411
TABLE 461 AMEGA BIOTECH: COMPANY OVERVIEW 413
TABLE 462 BIOCAD: COMPANY OVERVIEW 414
TABLE 463 PROBIOMED S.A. DE C.V.: COMPANY OVERVIEW 414
TABLE 464 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.: COMPANY OVERVIEW 415
TABLE 465 POLPHARMA BIOLOGICS GROUP: COMPANY OVERVIEW 416
TABLE 466 NEUCLONE: COMPANY OVERVIEW 417
TABLE 467 XENTRIA: COMPANY OVERVIEW 418
TABLE 468 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC: COMPANY OVERVIEW 419
TABLE 469 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.: COMPANY OVERVIEW 420
TABLE 470 CURATEQ BIOLOGICS PVT. LTD.: COMPANY OVERVIEW 421
TABLE 471 XBRANE BIOPHARMA AB: COMPANY OVERVIEW 422
TABLE 472 FORMYCON AG: COMPANY OVERVIEW 423
TABLE 473 SAM CHUN DANG PHARM. CO., LTD.: COMPANY OVERVIEW 424
TABLE 474 PRESTIGE BIOPHARMA: COMPANY OVERVIEW 425
TABLE 475 BIOEQ AG: COMPANY OVERVIEW 426
TABLE 476 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 436
FIGURE 1 BIOSIMILARS MARKET: SEGMENTS CONSIDERED 39
FIGURE 2 BIOSIMILARS MARKET: YEARS CONSIDERED 40
FIGURE 3 MARKET SCENARIO 43
FIGURE 4 GLOBAL BIOSIMILARS MARKET, 2024–2036 43
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMILARS MARKET,
2024–2036 44
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF BIOSIMILARS MARKET 45
FIGURE 7 HIGH-GROWTH SEGMENTS IN BIOSIMILARS MARKET, 2026–2036 46
FIGURE 8 MIDDLE EAST TO REGISTER HIGHEST CAGR IN BIOSIMILARS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 47
FIGURE 9 APPROVALS OF BIOSIMILARS TO DRIVE MARKET GROWTH 49
FIGURE 10 MONOCLONAL ANTIBODIES SEGMENT ACCOUNTED FOR LARGEST SHARE OF BIOSIMILARS MARKET IN NORTH AMERICA IN 2025 50
FIGURE 11 MEXICO LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL BIOSIMILARS MARKET DURING FORECAST PERIOD 51
FIGURE 12 ONCOLOGY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 51
FIGURE 13 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
FIGURE 14 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 15 BIOSIMILARS MARKET: VALUE CHAIN ANALYSIS 70
FIGURE 16 BIOSIMILARS MARKET: SUPPLY CHAIN ANALYSIS 72
FIGURE 17 BIOSIMILARS MARKET: ECOSYSTEM ANALYSIS 73
FIGURE 18 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, 2023–2025 (USD) 77
FIGURE 19 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION,
2023–2025 (USD) 79
FIGURE 20 BIOSIMILARS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 81
FIGURE 21 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 81
FIGURE 22 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET 100
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS 118
FIGURE 24 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER 120
FIGURE 25 EUROPE: BIOSIMILARS MARKET SNAPSHOT 250
FIGURE 26 MIDDLE EAST: BIOSIMILARS MARKET SNAPSHOT 301
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS, 2023–2025 (USD MILLION) 319
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 321
FIGURE 29 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 324
FIGURE 30 BIOSIMILARS MARKET: COMPANY FOOTPRINT 325
FIGURE 31 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 330
FIGURE 32 EV/EBITDA OF KEY VENDORS 333
FIGURE 33 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 333
FIGURE 34 BIOSIMILARS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 334
FIGURE 35 SANDOZ GROUP AG: COMPANY SNAPSHOT (2025) 339
FIGURE 36 AMGEN INC.: COMPANY SNAPSHOT (2025) 346
FIGURE 37 CELLTRION INC.: COMPANY SNAPSHOT (2025) 352
FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2025) 358
FIGURE 39 BIOCON: COMPANY SNAPSHOT (2025) 363
FIGURE 40 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2025) 369
FIGURE 41 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2025) 373
FIGURE 42 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2025) 375
FIGURE 43 FRESENIUS KABI AG.: COMPANY SNAPSHOT (2025) 380
FIGURE 44 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2025) 384
FIGURE 45 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 389
FIGURE 46 SAMSUNG BIOEPIS HOLDINGS CO., LTD.: COMPANY SNAPSHOT (2025) 392
FIGURE 47 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT (2025) 396
FIGURE 48 BIO THERA SOLUTIONS: COMPANY SNAPSHOT (2025) 399
FIGURE 49 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY SNAPSHOT (2025) 404
FIGURE 50 ALVOTECH: COMPANY SNAPSHOT (2025) 409
FIGURE 51 RESEARCH DESIGN 427
FIGURE 52 BREAKDOWN OF PRIMARY INTERVIEWS: BIOSIMILARS MARKET 430
FIGURE 53 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 431
FIGURE 54 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION), 2025 432
FIGURE 55 ILLUSTRATIVE EXAMPLE OF SANDOZ GROUP AG (SWITZERLAND):
REVENUE SHARE ANALYSIS (2025) 432
FIGURE 56 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 433
FIGURE 57 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 434
FIGURE 58 BIOSIMILARS MARKET: CAGR PROJECTIONS 435
FIGURE 59 DATA TRIANGULATION METHODOLOGY 437
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們